China’s Prestigious Oncology Event: 2024 CSCO Annual Meeting Held in Xiamen

China’s Prestigious Oncology Event: 2024 CSCO Annual Meeting Held in Xiamen

Xiamen, China, September 25-29, 2024 — The 27th National Clinical Oncology Conference and the 2024 Academic Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) commenced in Xiamen, embracing the theme "Patient-Centric, Shared Future." Jointly organized by the CSCO and the CSCO Foundation, the conference has brought together top experts and elites in oncology from both domestic and international fields to discuss the latest advancements, cutting-edge technologies, and future trends in cancer prevention and treatment.
Dr. Peiqi Zhao: New Drug Developments and Optimized Management – Upgrading the Comprehensive Treatment Strategy for Follicular Lymphoma

Dr. Peiqi Zhao: New Drug Developments and Optimized Management – Upgrading the Comprehensive Treatment Strategy for Follicular Lymphoma

From September 6 to 8, 2024, the 5th Tianjin International Lymphoma Conference was grandly held, attracting global experts to foster academic exchange and cooperation. During the conference, Hematology Frontier invited Dr. Peiqi Zhao from Tianjin Medical University Cancer Institute and Hospital to discuss the latest advances in follicular lymphoma treatment and the evolving concept of comprehensive disease management.
Dr. Lin Shen’s Team Confirms Promising Efficacy of Immunotherapy Combined with Chemotherapy as Neoadjuvant Treatment for Locally Advanced Esophageal

Dr. Lin Shen’s Team Confirms Promising Efficacy of Immunotherapy Combined with Chemotherapy as Neoadjuvant Treatment for Locally Advanced Esophageal

In April 2024, the 115th Annual Meeting of the American Association for Cancer Research (AACR) was held in San Diego, USA. As a global bellwether for new cancer drug development, the AACR meeting showcased numerous cutting-edge research findings in the field of oncology. One such study, conducted by Dr. Lin Shen's team from Peking Cancer Hospital, evaluated camrelizumab combined with chemotherapy as a neoadjuvant treatment for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC). This single-center, randomized, Phase II trial was selected for poster presentation at the conference, and Oncology Digest - Digestive Oncology News has summarized the key findings for readers.
Dr. Xiubao Ren: Exploring Tumor Immunotherapy from a “Reverse” Perspective – The Practice of Reverse Immune Editing Therapy

Dr. Xiubao Ren: Exploring Tumor Immunotherapy from a “Reverse” Perspective – The Practice of Reverse Immune Editing Therapy

The 5th Tianjin International Lymphoma Conference was successfully held from September 6 to 8, 2024. The conference featured 12 specialized sessions, including immunotherapy, basic translational research, and new drug development, providing a platform for international academic exchange and collaboration. During the event, Hematology Frontier invited Dr. Xiubao Ren from Tianjin Medical University Cancer Institute and Hospital to share insights on the progress of clinical trials in reverse immune editing therapy and its future application prospects in cancer treatment.
Dr. Shuquan Cheng: Common Factors Hindering Functional Cure in Chronic Hepatitis B

Dr. Shuquan Cheng: Common Factors Hindering Functional Cure in Chronic Hepatitis B

The reduction of hepatitis B surface antigen (HBsAg) levels in treated chronic hepatitis B (CHB) patients is closely linked to decreased risks of cirrhosis and even liver cancer. However, spontaneous HBsAg clearance occurs in less than 1% of patients per year. As CHB prevention and treatment guidelines continue to evolve both domestically and internationally, more patients are now pursuing "functional cures" through nucleos(t)ide analogs (NAs) combined with or followed by pegylated interferon (PEG-IFN) treatment. This approach offers the possibility of reducing or eliminating long-term or lifelong medication use. Clinically, even when patients use similar regimens aimed at achieving a functional cure, many continue to struggle along the difficult path to achieving HBsAg seroclearance, let alone reaching the ideal treatment endpoint of HBs seroconversion. Thus, understanding and recognizing the potential factors influencing functional cure is crucial for timely evaluation and intervention. This article summarizes the possible factors affecting CHB functional cure based on both domestic and international research to date.
Chinese Innovative Drug Takes the International Stage, Offering New Treatment Options for Intermediate and High-Risk Myelofibrosis Patients

Chinese Innovative Drug Takes the International Stage, Offering New Treatment Options for Intermediate and High-Risk Myelofibrosis Patients

From September 13 to 17, 2024, the European Society for Medical Oncology (ESMO) Annual Meeting is being held in Barcelona, Spain. As one of the top international oncology conferences, the event gathers experts and scholars from around the world to share cutting-edge research and discuss future developments. In the Mini Oral Session on Hematologic Malignancies, Dr. Ling Pan from West China Hospital, Sichuan University, presented a pivotal phase II study comparing rovatirelinib with hydroxyurea for the treatment of intermediate and high-risk myelofibrosis (MF). The results demonstrated significant benefits in both efficacy and safety for rovatirelinib, offering a new potential treatment option for MF patients. Hematology Frontier invited Dr. Ling Pan to discuss the current landscape and challenges in the diagnosis and treatment of MF, provide insights into this pivotal study, and share her experiences at the ESMO conference.
BV Combined with R2 Regimen Significantly Improves Overall Survival in Patients with Relapsed/Refractory DLBCL

BV Combined with R2 Regimen Significantly Improves Overall Survival in Patients with Relapsed/Refractory DLBCL

The treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has always been a significant challenge and a hot topic in the field of hematologic malignancies. For these patients, treatment options are extremely limited after multiple lines of therapy. Their salvage therapy has a low remission rate and short survival time. Currently, there is an urgent need for new effective treatment regimens to improve patient outcomes. The 12th Annual Meeting of the Society for Hematologic Oncology (SOHO 2024) was held in Houston, USA, from September 4th to 7th, 2024, bringing together top experts in the field of hematologic malignancies worldwide to exchange the latest research findings and discuss new therapeutic strategies. During the conference, Dr. Christopher A. Yasenchak from the Willamette Valley Cancer Institute and Rsearch Center was selected for an oral presentation titled 'Brentuximab Vedotin (BV) in Combination With Lenalidomide (Len) and Rituximab (R) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results From the Phase 3 ECHELON-3 Study' (Abstract Number: ABCL-711). Hematology Frontier specially invited Professor Christopher A. Yasenchak to interpret the efficacy and clinical significance of the BV+R2 (Brentuximab Vedotin combined with Rituximab and Lenalidomide) regimen in the ECHELON-3 study.